Purdue Pharma Cuts More Than Half of U.S. Sales Staff Amid Opioid Crisis Post author:Sam Post published:February 12, 2018 Post category:BioPharma That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past. Source: BioSpace You Might Also Like How Gilead's $12 Billion Kite Pharma Deal Has Already Paid Off for Investors September 18, 2017 Epinex Diagnostics To Present At The BIO CEO & Investor Conference February 9, 2017 Athenex Moves Forward With $205M New York Plant January 11, 2018